Lipocine Inc. (NASDAQ:LPCN – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $6.60 and traded as high as $8.71. Lipocine shares last traded at $7.72, with a volume of 22,285 shares changing hands.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on Lipocine in a report on Monday, May 13th. They set a “hold” rating for the company.
Lipocine Stock Down 6.3 %
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $0.66 earnings per share for the quarter. The business had revenue of $7.62 million for the quarter. As a group, equities analysts expect that Lipocine Inc. will post -1 EPS for the current fiscal year.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Recommended Stories
- Five stocks we like better than Lipocine
- Health Care Stocks Explained: Why You Might Want to Invest
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Are Dividend Champions? How to Invest in the Champions
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.